ADZYNMA

What is this medication? ADZYNMA is a prescription medicine used for prophylactic or on-demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura, also known as cTTP. This rare and life-threatening blood clotting disorder is caused by a deficiency in the ADAMTS13 enzyme, which leads to the formation of small blood clots throughout the body. By providing a recombinant form of this specific enzyme, the medication helps to regulate blood clotting and prevents the depletion of platelets and the destruction of red blood cells.

The medication is typically administered as an intravenous injection and works by replacing the missing ADAMTS13 protein in the bloodstream. Regular use of ADZYNMA as a preventative treatment can reduce the frequency of acute episodes and long-term complications associated with cTTP, such as organ damage or stroke. It may also be used during an acute event to quickly restore enzyme levels and manage symptoms. Patients and caregivers should work closely with healthcare providers to monitor for potential side effects and ensure the correct dosage based on individual needs.